This activity is intended for specialist pulmonary providers who participate in the care of patients with severe asthma including general pulmonologists, interventional pulmonologists, thoracic surgeons, physicians-in-training, nurses including nurse navigators, and physician extenders.
Upon completion of the educational activity, participants should be able to:
- Describe the mechanisms of action and clinical trial data relating to the safety and efficacy of current and emerging therapies for severe asthma.
CME Credit provided by The American Thoracic Society
CME Accreditation Statement and Credit Designation
The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Thoracic Society designates this live activity for a maximum of 1 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
CE Credit provided by AKH Inc., Advancing Knowledge in Healthcare
AKH, Inc., Advancing Knowledge in Healthcare is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 1 Contact Hours.
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.
This activity is approved for 1.00 contact hour(s) which includes 0.5 hour(s) of pharmacology. Activity ID # 22067-2
This activity was planned in accordance with AANP Accreditation Standards and Policies.
This educational activity is supported by an educational grant from GlaxoSmithKline.
Criteria for Success
Statements of credit will be awarded based on the participant's attendance, participation in the pre/post-test and submission of the activity evaluation form. A passing score of 70% on the quiz is required to receive credit. A certificate will be available in your transcripts upon successful completion of the quiz and evaluation. If you have questions about this CME/CE activity, please contact AKH Inc. at email@example.com. There is no fee for this activity.
ABOUT OUR FACULTY
Njira Lugogo, MD
Division of Pulmonary, Critical Care Medicine
Director Michigan Medicine Asthma Program
University of Michigan, MI
Njira Lugogo, MD, MS, Associate Professor of Internal Medicine, is the Division of Pulmonary & Critical Care Medicine's Asthma Program Director. Dr. Lugogo completed her Medical Degree at the Medical College of Virginia, Richmond, VA. She completed her Internal Medicine Residency at Wake Forest University, Winston-Salem, NC. After she completed her Pulmonary & Critical Care Medicine Fellowship at Duke University, she rose to Assistant Professor. At Duke, Dr. Lugogo served as the Medical Director of the Duke Asthma Allergy and Airway Center and Director of the Asthma Clinical Trails Group and Pulmonary Clinical Research Unit. She joined the University of Michigan Pulmonary & Critical Care Medicine faculty August, 2017.
Dr. Lugogo has disclosed the following relevant financial relationships:
Advisory Committee for non-promotional: AstraZeneca, Genentech, GlaxoSmithKline, Novartis, Sanofi/Regeneron
Research support - industry initiated(e.g. trials): AstraZeneca, GlaxoSmithKline, Sanofi/Regeneron
Speaker/faculty - non-promotional: AstraZeneca
Laren Tan, MD
Associate Professor of Medicine
Division of Pulmonary, Critical Care, Hyperbaric, Allergy and Sleep Medicine
Director LLUH Comprehensive Program for Obstructive Airway Diseases
Loma Linda University Health
Loma Linda, CA
Laren Tan is Associate Professor of Medicine at Loma Linda University. Professor Tan is the creator and director of the University’s Comprehensive Program for Obstructive Airway Diseases. During his tenure as Director, the University has become the regional referral center for advanced biologic therapy for severe asthmatics and has achieved national recognition as a center of excellence for the provision of bronchial thermoplasty. As part of the interdisciplinary Obstructive Airway Disease team, Professor Tan provides comprehensive, personalized, conventional and advanced therapies for patients with the most severe obstructive airway diseases.
Dr. Tan has disclosed the following relevant financial relationships:
Advisory Committee for promotional purpose: AstraZeneca, Boston Scientific, Genentech, GlaxoSmithKline, Regeneron
Speaker/faculty - promotional: Boehringer-Ingelheim, Sanofi Genzyme
Josalyn L. Cho, MD
Assistant Professor of Internal Medicine
Pulmonary, Critical Care and Occupational Medicine
University of Iowa Carver College of Medicine
Iowa City, IA
Dr. Cho has no financial relationships to disclose.
AKH STAFF AND PLANNERS
Margaret V. Clark, MSc, RN, RRT - NPS, CMPP, Medical Writer/Interviewer: has no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.
Suzette Machado, MPA, CHCP, Associate Director of Education Programs and Accreditation; has no financial relationships to disclose
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. ATS and AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
It is the policy of ATS and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by ATS and AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Copyright 2020 ATS and AKH Inc. No part of this publication may be produced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical photocopying, recording, or otherwise, without the prior permission of the publisher.